Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines

Montoya, José G.; Adams, A. Elizabeth; Bonetti, Valérie; Deng, Sien; Link, Nan A; Pertsch, Suzanne; Olson, Kjerstie; Li, Martina; Dillon, Ellis C; Frosch, Dominick L.

doi:10.1128/spectrum.01162-21

Cited by 33 publications

(38 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A higher frequency of the BNT162b2 vaccine was associated with a lower seroconversion rate in IBD patients in the included studies. Our results are in accordance with previous studies 46,47 Therefore, further studies are necessary to evaluate the influence of the country site with the seroconversion rate.…”

Section: Discussionsupporting

confidence: 92%

Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

Bhurwal

Mutneja

Bansal

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Introduction: There are concerns regarding the effectiveness and safety of SARS-CoV-2 vaccine in inflammatory Bowel Disease (IBD) patients. This systematic review and meta-analysis comprehensively summarises the available literature regarding the safety and effectiveness of SARS-CoV-2 vaccine in IBD. Methods: Three independent reviewers performed a comprehensive review of all original articles describing the response of SARS-CoV-2 vaccines in patients with IBD. Primary outcomes were (1) pooled seroconversion rate SARS-CoV-2 vaccination in IBD patients (2) comparison of breakthrough COVID-19 infection rate SARS-CoV-2 vaccination in IBD patients with control cohort and (3) pooled adverse event rate of SARS-CoV-2 vaccine. All outcomes were evaluated for one and two doses of SARS-CoV-2 vaccine. Meta-regression was performed. Probability of publication bias was assessed using funnel plots and with Egger's test.Results: Twenty-one studies yielded a pooled seroconversion rate of 73.7% and 96.8% in IBD patients after one and two doses of SARS-CoV-2 vaccine respectively. Sub-group analysis revealed non-statistically significant differences between different immunosuppressive regimens for seroconversion. Meta-regression revealed that the vaccine type and study location independently influenced seroconversion rates.There was no statistically significant difference in breakthrough infection in IBD patients as compared to control after vaccination. Conclusion:In summary, the systematic review and meta-analysis suggest that SARS-CoV-2 vaccine is safe and effective in IBD patients.

show abstract

Section: Discussionsupporting

confidence: 92%

Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

Bhurwal

Mutneja

Bansal

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…The current findings indicate that BNT162b2 and mRNA-1273 both achieve similar peak IgG levels to the SARS-CoV-2 spike RBD antigen following two vaccine doses. Although this finding is at odds with some earlier reports ( 11 , 20 , 21 ), including an interim analysis of the current cohort ( 12 ), it is at least partially explained by different rates of antibody decay that occur following immunization with BNT162b2 and mRNA-1273 and is supported by a recent report from Montoya et al ( 22 ). The detailed kinetic analysis here reveals that IgG levels in recipients of BNT162b2 are dropping markedly (eg, 40%), and to a greater extent than mRNA-1273, as soon as 21 days after the booster immunization.…”

Section: Discussioncontrasting

confidence: 56%

Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection

et al. 2022

View full text Add to dashboard Cite

Three COVID-19 vaccines have received FDA-authorization and are in use in the United States, but there is limited head-to-head data on the durability of the immune response elicited by these vaccines. Using a quantitative assay we studied binding IgG antibodies elicited by BNT162b2, mRNA-1273 or Ad26.COV2.S in an employee cohort over a span out to 10 months. Age and sex were explored as response modifiers. Of 234 subjects in the vaccine cohort, 114 received BNT162b2, 114 received mRNA-1273 and six received Ad26.COV2.S. IgG levels measured between seven to 20 days after the second vaccination were similar in recipients of BNT162b2 and mRNA-127 and were ~50-fold higher than in recipients of Ad26.COV2.S. However, by day 21 and at later time points IgG levels elicited by BNT162b2 were lower than mRNA-1273. Accordingly, the IgG decay curve was steeper for BNT162b2 than mRNA-1273. Age was a significant modifier of IgG levels in recipients of BNT162b2, but not mRNA-1273. After six months, IgG levels elicited by BNT162b2, but not mRNA-1273, were lower than IgG levels in patients who had been hospitalized with COVID-19 six months earlier. Similar findings were observed when comparing vaccine-elicited antibodies with steady-state IgG targeting seasonal human coronaviruses. Differential IgG decay could contribute to differences observed in clinical protection over time between BNT162b2 and mRNA-1273.

show abstract

“…Antibody levels were comparable to those recently published in a large cohort of health care workers with mean antibody levels of 760, 688, and 501 BAU/ml after 1, 2, and 3 months, respectively. 7 Our observation of declining antibody levels was further confirmed in six patients where individual follow-up measurements of the vaccination levels were available. Here, all patients except for one (patient #10, Table 1) showed declining antibody levels over time (Figure 1B).…”

Section: Analysis Of the Vaccination-induced Antibody Levels Againstsupporting

confidence: 65%

“…Furthermore, we observed that antibody levels in AA patients declined after second vaccination as previously reported for healthy individuals. 7 For all patients who received a third vaccination, we found a substantial increase in…”

Section: Analysis Of the Vaccination-induced Antibody Levels Againstmentioning

confidence: 75%

“…Since antibody levels against the SARS‐CoV‐2 spike protein are known to rapidly decrease within the first weeks after second vaccinations in healthy individuals, 7 we stratified our patients antibody titers in a cross‐sectional approach according to the time after second vaccination. Here, we found a continuous decline in antibody levels from a median of 848 BAU/ml (range 176–1040 BAU/ml) after the 1st month to 410 BAU/ml (range 168–1040 BAU/ml) in the 2nd month and to 367 BAU/ml (range 223–936 BAU/ml) after 3 to 6 months after the second vaccination (Figure 1A ).…”

Section: Tablementioning

confidence: 99%

See 1 more Smart Citation

Antibody titers after SARS‐CoV‐2 mRNA vaccination in patients with aplastic anemia—A single‐center study

Walter

Kricheldorf

Isfort

et al. 2022

European J of Haematology

View full text Add to dashboard Cite

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines

Cited by 33 publications

References 16 publications

Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection

Antibody titers after SARS‐CoV‐2 mRNA vaccination in patients with aplastic anemia—A single‐center study

Contact Info

Product

Resources

About